

# Complementary and Alternative Medicine Therapies for Diabetes: A Clinical Review

Gurjeet S. Birdee, MD, MPH, and Gloria Yeh, MD, MPH

Complementary and alternative medicine (CAM) refers to a wide range of clinical therapies outside of conventional medicine.<sup>1</sup> The term “complementary” refers to therapies that are used in conjunction with conventional medicine, whereas “alternative” medicine includes therapies that are used in place of conventional medicine. The term “integrative” medicine has been advocated by some CAM providers and researchers as representing a combination of conventional medicine, CAM, and evidence-based medicine.<sup>2</sup>

The National Center for Complementary and Alternative Medicine, a federal scientific agency for CAM research, categorizes CAM into five domains: biologically based practices, mind-body medicine, manipulation and body-based practices, energy medicine, and whole-medical systems (Table 1). Biologically based practices and mind-body medicine are the most common CAM modalities used and studied for the treatment of diabetes in the West and are the focus of this review.

In the United States, CAM is frequently used by adults, with 40% reporting use in the past 12 months.<sup>3</sup> An estimated 34% of adults with diabetes use some type of CAM therapy.<sup>4</sup> The estimated out-of-pocket expense in 2007 on CAM therapies was \$44 billion.<sup>5</sup>

Although some CAM therapies have been shown to affect glycemic control, the clinical efficacy and

mechanism of many CAM therapies for diabetes is controversial, and safety issues are a concern. Adverse effects of many CAM therapies are not well documented. Because patients with diabetes often take multiple prescription medications, there exists the potential for herb-drug and herb-dietary supplement interactions, leading to adverse events.<sup>6,7</sup> At least 63% of the general population do not disclose use of CAM therapies to their physicians.<sup>8</sup>

The purpose of this clinical review is to discuss selected CAM therapies frequently used for patients with diabetes and to provide a framework to advise patients on CAM use.

## Biologically Based Practices: Herbs and Supplements

### IN BRIEF

More than one-third of patients with diabetes in the United States use some type of complementary and alternative medicine (CAM). Herbs, dietary supplements, and mind-body medicine are the most commonly used and studied CAM modalities to treat diabetes. This article provides an overview of CAM for diabetes, including proposed mechanisms, a summary of evidence, and adverse effects. It also offers recommendations for counseling patients regarding CAM use.

## Definition, regulation, and safety

In 1994, the Dietary Supplement Health and Education Act (DSHEA), approved by the U.S. Congress, defined dietary supplements as products taken by mouth that contain vitamins, minerals, herbs, or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandular substances, and metabolites. Supplements can take different forms, including tablets, capsules, soft gels, gel capsules, liquids, or powders.

Importantly, DSHEA treats dietary supplements as a type of food rather than as drugs. Under this bill, dietary supplements do not need U.S. Food and Drug Administration (FDA) approval before marketing, and manufacturers are not mandated to establish the quality, efficacy, or safety of products. Manufacturers cannot make specific clinical claims that supplements can treat or cure a specific condition. However, nonspecific statements are allowed, such as proclamations that the product “supports,” “promotes,” or “enhances” specific organ systems. For example, a supplement manufacturer cannot state on the product label that the substance “reduces blood glucose in patients with diabetes,” but may state that the product “supports glucose tolerance.”

After marketing, the FDA is responsible for determining whether dietary supplements are “unsafe.” In 2007, the FDA established a new set of regulations called Good

**Table 1. Types of Complementary and Alternative Medicine<sup>1</sup>**

| CAM Therapy                           | Description   | Examples   |
|---------------------------------------|---|--|
| Biologically based practices          | Therapies involving substances found in nature that have purported medicinal properties                                       | Herbs and dietary supplements such as vitamins and foods   |
| Mind-body medicine                    | Practices that use the relationship of mind and body to achieve improved health or treat disease                              | Yoga, tai chi, and meditation  |
| Manipulation and body-based practices | Practices that manipulate or move specific body parts or the whole body   | Chiropractic therapy, osteopathic manipulation, and massage  |
| Energy medicine                       | Practices involving belief in energy fields around and inside the human body that are altered by providers for health benefit | Reiki, external qi gong, and therapeutic touch   |
| Whole medical systems                 | Complete medical systems that often evolved separately from or earlier than conventional medicine                             | Homeopathy, naturopathy, <i>Ayurveda</i> (traditional medicine from India), and traditional Chinese medicine |

Manufacturing Practices to improve the quality of dietary supplements by requiring the industry to appropriately label and ensure the purity, strength, and composition of all dietary supplements. These regulations are scheduled to be phased in by this year. Therefore, their successful implementation cannot yet be evaluated.

The high consumer demand, large supplement industry, and current regulatory framework yield a wide range of products with different compositions and uncertain safety and efficacy. In a 2008 position statement, the American Diabetes Association (ADA) stated that there is insufficient evidence to demonstrate the efficacy of supplements in diabetes management and recognized the lack of standardization among preparations.<sup>9</sup> In the following discussion, we summarize selected herbs and dietary supplements that are commonly used for patients with diabetes and that clinicians may encounter in practice (Table 2).

**Botanical products for diabetes treatment**

**Allium sativum (garlic).** Found in many kitchens, *allium sativum* (garlic), has also been used for medicinal purposes around the world. A majority of contemporary medical use and research for garlic has focused on treatment of cardiovascular-related diseases.

In clinical trials, garlic supplementation among patients with dyslipidemia produced modest reduction in total cholesterol with no significant changes in LDL or HDL cholesterol levels.<sup>10,11</sup> Pooled data from clinical trials of patients with hypertension have shown significant decreases in systolic (8.4 ± 2.8mmHg) and diastolic (7.3 ± 1.5mmHg) blood pressure levels in patients using garlic treatment compared to control groups.<sup>12</sup> Less research has been conducted among patients with diabetes. Limited animal studies have suggested that the chemical components of garlic may increase insulin secretion or decrease degradation.<sup>10,11</sup> Clinical trials of oral garlic in patients with type 2 diabetes have not demonstrated significant

changes in blood glucose or insulin levels.<sup>12,13</sup>

**Aloe vera.** This desert plant is the source of the common gel used topically for dermatological conditions. In the Arabian peninsula, parts of the aloe plant have been used orally as a traditional treatment for diabetes. The gel derived from the meaty pulp of the leaf, taken orally, may produce hypoglycemic effects through β-cell stimulation.<sup>13,14</sup>

Two controlled, nonrandomized trials in patients with type 2 diabetes who were given aloe gel juice reported decreases in fasting blood glucose during 6 weeks.<sup>15,16</sup> However, these studies lacked sufficient details in reporting, including study design and results, leading to inconclusive evidence. In contrast to the gel, aloe latex from the inner lining of the leaf contains a harsh anthroquinone laxative that may be unsafe.<sup>17</sup>

**Coccinia indica (ivy gourd).** *Ayurveda* is a traditional medical system from the Indian subcontinent that often uses herbs for treatment. The creeper plant *coccinia indica* is prescribed in *Ayurveda* for the treatment of diabetes. *Coccinia* may produce hypoglycemia in a mechanism similar to

**Table 2. Selected Biologically Based Practices Used for Diabetes**

| Name   | Hypothesized Effect(s) on Glucose Metabolism  | Potential Adverse Effects*  |
|--|---|---|
| <b>Botanicals</b>  |   |   |
| <i>Allium sativum</i> (garlic)   | <ul style="list-style-type: none"> <li>• Insulin secretagogue</li> </ul>  | <ul style="list-style-type: none"> <li>• Blood thinning (use caution with anti-coagulation or anti-platelet medications)</li> </ul>   |
| Aloe vera  | <ul style="list-style-type: none"> <li>• Insulin secretagogue</li> </ul>  | <ul style="list-style-type: none"> <li>• Abdominal pain, diarrhea from laxative component, with subsequent electrolyte depletion</li> </ul>   |
| <i>Coccinia indica</i> (ivy gourd)   | <ul style="list-style-type: none"> <li>• Insulin mimetic</li> </ul>   | <ul style="list-style-type: none"> <li>• None reported</li> </ul>   |
| <i>Gymnema sylvestre</i> (gymnema)   | <ul style="list-style-type: none"> <li>• Insulin secretagogue</li> </ul>  | <ul style="list-style-type: none"> <li>• Suppression of sweet taste</li> </ul>  |
| <i>Momordica charantia</i> (bitter melon)  | <ul style="list-style-type: none"> <li>• Insulin mimetic</li> <li>• Decreased hepatic glucose production</li> </ul>   | <ul style="list-style-type: none"> <li>• Glucose-6-phosphate deficiency</li> <li>• Contraindicated in pregnancy</li> </ul>  |
| <i>Opuntia streptacantha</i> (prickly pear cactus, nopal)  | <ul style="list-style-type: none"> <li>• Decreased carbohydrate absorption</li> </ul>                                 | <ul style="list-style-type: none"> <li>• Diarrhea, nausea, abdominal fullness</li> </ul>  |
| <i>Panax ginseng</i> , <i>P. quiquefolius</i> (ginseng)  | <ul style="list-style-type: none"> <li>• Insulin mimetic</li> <li>• Alters hepatic glucose metabolism</li> </ul>      | <ul style="list-style-type: none"> <li>• May interfere with effect of anti-coagulation and anti-platelet medications</li> <li>• Estrogenic effect with breast tenderness, amenorrhea, vaginal bleeding, impotence</li> <li>• Hypertension</li> <li>• Insomnia</li> </ul>                                |
| <i>Trigonella foenum graecum</i> (fenugreek)   | <ul style="list-style-type: none"> <li>• Insulin secretagogue</li> <li>• Decreased carbohydrate absorption</li> </ul> | <ul style="list-style-type: none"> <li>• Gas, bloating, diarrhea</li> <li>• Contraindicated in pregnancy</li> </ul>   |
| <b>Supplements</b>   |   |   |
| Alpha-lipoic acid  | <ul style="list-style-type: none"> <li>• Increased insulin sensitivity</li> </ul>                                     | <ul style="list-style-type: none"> <li>• Monitor thyroid function in patients with thyroid disease</li> </ul>   |
| Chromium   | <ul style="list-style-type: none"> <li>• Increased insulin sensitivity</li> </ul>                                     | <ul style="list-style-type: none"> <li>• Minimal</li> </ul>   |
| Coenzyme Q10   | <ul style="list-style-type: none"> <li>• No effect on blood glucose</li> </ul>  | <ul style="list-style-type: none"> <li>• Few reported in clinical trials</li> </ul>   |
| Magnesium  | <ul style="list-style-type: none"> <li>• Insulin secretagogue</li> <li>• Increased insulin sensitivity</li> </ul>     | <ul style="list-style-type: none"> <li>• Diarrhea, abdominal cramping</li> <li>• Magnesium toxicity in individuals with renal failure</li> </ul>  |
| Omega-3 fatty acids  | <ul style="list-style-type: none"> <li>• Slight increase in blood glucose</li> </ul>                                  | <ul style="list-style-type: none"> <li>• Intake &gt; 3 g may increase risk of bleeding</li> <li>• Fish meat may have high levels of methylmercury; to be eaten with caution by children and pregnant/breastfeeding women</li> <li>• May increase LDL; caution in patients with very high LDL</li> </ul> |
| Vanadium   | <ul style="list-style-type: none"> <li>• Insulin mimetic</li> </ul>   | <ul style="list-style-type: none"> <li>• Prolonged high doses may cause renal toxicity</li> </ul>   |
| <p>*All biologically based practices that may reduce blood glucose have the potential for interacting with conventional diabetes medications, producing hypoglycemia. This is not a comprehensive list of potential adverse effects.</p> |   |   |

insulin.<sup>18</sup> Two randomized, controlled trials (RCTs)<sup>19,20</sup> and one controlled, nonrandomized trial<sup>18</sup> have suggested decreases in fasting blood glucose without adverse effects among type 2 diabetes patients after administration of *coccinia*. In one of these studies,<sup>20</sup> 60 subjects were randomized to *coccinia* or placebo. Patients who received the herb had a 16% decrease in fasting blood glucose.

Although data are suggestive of a therapeutic effect for *coccinia*, further research is necessary to determine optimal preparations, dose, mechanisms, and safety.

**Gymnema sylvestre** (*gymnema*). This botanical has also been used for two centuries in *Ayurveda* for the treatment of diabetes. Traditionally, the leaves of the plant are chewed, which can suppress the sweet taste sensation, giving rise to its Hindi name *gurmara*, or “sugar destroyer.” In addition to affecting taste, the herb has demonstrated hypoglycemic effects in animal and human studies, perhaps functioning as an insulin secretagogue.<sup>21,22</sup>

An extract of *gymnema* leaf, called GS4, has been studied as an adjuvant therapy to conventional care in two controlled, nonrandomized trials of patients with type 1 and type 2 diabetes, respectively.<sup>23,24</sup> Both studies reported significant before-to-after improvements in fasting blood glucose and A1C levels among patients receiving GS4. No significant before-to-after changes were reported in the control groups. These studies lacked between-group comparisons and randomization, precluding definitive evidence for *gymnema* for the treatment of diabetes.

**Momordica charantia** (*bitter melon*). This tropical vegetable, grown in Africa, Asia, and South America, is known as bitter melon, or “vegetable insulin.” It may reduce blood glucose in patients with diabetes.<sup>25,26</sup>

Potential mechanisms of action for bitter melon are decreased hepatic glucose production, increased hepatic glycogen synthesis,<sup>27</sup> and insulin-mimetic activity.<sup>28,29</sup> Most clinical trials of bitter melon among patients with diabetes have lacked adequate design to determine clinical effectiveness.<sup>26,30</sup>

**Opuntia streptacantha** (*prickly pear cactus, nopal*). Found in desert regions of North America, nopal is used in Mexican cuisine and indigenous medicine. Mexican-American patients with diabetes have reported using nopal for glucose control.<sup>31</sup> Few studies of nopal have been published in English, and these have explored acute metabolic effects rather than clinical outcomes.<sup>32,33</sup>

**Panax ginseng, P. quiquefolius** (*ginseng*). The panax genus contains multiple species described as ginseng, with two varieties most frequently used and studied: panax ginseng (Asian ginseng, Chinese ginseng, Korean ginseng) and panax quinquefolius (American ginseng). The root of this herb traditionally has been used in Asia and is one of the most popular botanicals in the United States.<sup>3</sup>

Ginseng has many proposed health benefits, including improved general well-being, increased concentration, and treatment of cardiovascular disease and diabetes (*panax* is cognate to panacea). Ginseng can cause hypoglycemia, perhaps through activity similar to insulin or by altering hepatic glucose metabolism.<sup>34</sup>

Buettner et al., in a systematic review,<sup>35</sup> found conflicting clinical data of ginseng's effect on blood glucose in diabetic and nondiabetic populations. Variations in response may reflect chemical heterogeneity of different ginseng batches used in studies.<sup>36,37</sup>

**Trigonella foenum graecum** (*fenugreek*). Fenugreek is grown in North America and Asia and often flavors Indian food. It has been used

as medicine for diabetes in India and China. Mechanisms proposed for fenugreek in diabetes are decreased carbohydrate absorption and increased insulin secretion.

Several clinical trials among patients with type 1 or type 2 diabetes suggest a potential effect, but studies thus far have lacked sufficient quality.<sup>38,39</sup>

#### Dietary supplements for diabetes

**Alpha-lipoic acid (ALA)**. ALA is a chemical compound that is found in food (especially high in spinach, broccoli, and tomatoes), produced endogenously, and sold as a nutritional supplement. As an antioxidant, ALA may mitigate high levels of oxidative stress, which in patients with diabetes contributes to insulin resistance and secondary complications such as diabetic neuropathy.<sup>40</sup>

Acute intravenous ALA therapy (1–10 days) has been reported to improve insulin sensitivity.<sup>41,42</sup> A randomized, placebo-controlled trial of ALA supplementation in patients with type 2 diabetes<sup>43</sup> showed a 25% increase in insulin sensitivity after 4 weeks of ALA therapy at doses of 600–1,800 mg. The long-term effects of ALA have yet to be determined, although one study of patients with type 2 diabetes showed improved glycemic control after 12 weeks of therapy.<sup>44</sup>

**Chromium**. As an essential mineral, chromium plays an important role in facilitating glucose metabolism. Whole grains, egg yolks, broccoli, and brewer's yeast have high quantities of chromium.<sup>45</sup> Although rare, severe states of chromium deficiency are associated with reversible diabetes because of insulin resistance.<sup>46,47</sup> These observations have fueled marketing of chromium for individuals with diabetes who are not necessarily deficient in chromium to increase insulin sensitivity.

A meta-analysis of 14 RCTs<sup>48</sup> of patients with type 2 diabetes ( $n = 381$ ) concluded that there were significant changes in glucose metabolism after supplementation with chromium. Overall, the authors emphasized the poor quality of studies and the need for further research. Reports suggest that response to chromium may be dependent on individual patient phenotypes with those with high insulin resistance being most responsive.<sup>49–51</sup>

**Coenzyme Q10.** Coenzyme Q10 is a cofactor used in oxidative respiration and is produced endogenously. Supplementation of coenzyme Q10 is especially popular for cardiovascular diseases. Two RCTs of patients with type 2 diabetes and a single RCT of patients with type 1 diabetes produced no strong evidence for glycemic control with coenzyme Q10 supplementation.<sup>52,53</sup>

**Magnesium.** Magnesium is an abundant mineral in the human body involved in numerous biochemical processes, including glucose metabolism. Dietary sources of magnesium include whole grains, beans, nuts, and green, leafy vegetables. Magnesium deficiency is associated with poor glucose control in patients with diabetes.<sup>54</sup> However, in clinical trials, supplementation of magnesium has not yielded clear long-term positive benefits in type 2 diabetes.

Song et al.<sup>55</sup> conducted a meta-analysis compiling data from nine RCTs with a total of 370 subjects with type 2 diabetes. The duration of the studies ranged from 4 to 16 weeks and the studies administered a median magnesium dose of 15 mmol/day (360 mg/day) to active-treatment groups. The mean post-intervention fasting glucose after 12 weeks of treatment was significantly lower among active-treatment compared to placebo groups:  $-0.56$  mmol/l (95% CI  $-1.10$  to  $-0.01$ ). The difference in

post-intervention A1C was not significant.

Observational data suggest that magnesium supplementation may decrease the risk of type 2 diabetes. A meta-analysis in 2007<sup>56</sup> included seven prospective cohort studies that collected dietary and supplementary magnesium intake and incidence of type 2 diabetes. The relative risk for the development of type 2 diabetes with a 100 mg/day increase in magnesium was 0.85 (95% CI 0.79–0.92).

**Omega-3 fatty acid.** Omega-3 polyunsaturated fatty acids (PUFAs) are one of the most common dietary supplements taken in the United States.<sup>3</sup> Major sources of omega-3 PUFAs include fish, marine-derived supplements, and prescription formulations (sold under the trade names Omacor and Lovaza).

In the general population, observational studies and RCTs indicate reductions in coronary artery disease and sudden cardiac death based on omega-3 PUFA intake.<sup>57,58</sup> In patients with type 2 diabetes, a meta-analysis of omega-3 PUFA supplementation<sup>59</sup> that pooled data from 23 RCTs with a total of 1,075 patients did not show any significant changes in fasting glucose, A1C, or fasting insulin.

With a mean intake of 3.5 g/day of omega-3 PUFAs, significant decreases in triglycerides ( $-0.45$  mmol/l, 95% CI  $-0.58$  to  $-0.32$ ) and VLDL cholesterol ( $-0.07$  mmol/l, 95% CI  $-0.13$  to 0.00) and increases in LDL cholesterol (0.11 mmol/l, 95% CI 0.00–0.22) were noted. Subanalysis of patients with hypertriglyceridemia demonstrated no significant increase in LDL. Based on multiple studies, high omega-3 PUFA intake does not prevent the onset of type 2 diabetes.<sup>60</sup>

**Vanadium.** Vanadium is a mineral with no known biological importance or deficiency-associated disease.<sup>39,61</sup> Although three controlled studies of

vanadium for type 2 diabetes reported significant decreases in fasting blood glucose levels, small sample sizes and lack of randomization limit these results.<sup>62–64</sup>

### Mind-Body Medicine

Mind-body medicine is based on the concept that the physical body and mind influence each other. It uses specific techniques to affect this connection for the benefit of health. Mind-body techniques have arisen in various cultures and contexts. Some mind-body techniques, such as cognitive-behavioral therapy, bio-feedback, and hypnosis, have been adapted into mainstream medical culture and usually are not considered CAM.

Within CAM, most mind-body therapies have derived from Eastern traditions, such as yoga, tai chi, and meditation. Yoga, a mind-body practice from India, has become increasingly popular in the West to promote health. The practice of yoga may include techniques of movement, breathing, meditation, chanting, and lifestyle change. Tai chi is a mind-body practice from China with roots in martial arts and ancient healing traditions. Tai chi consists of coordinated gentle movements with mental focus, breathing, and relaxation.<sup>65</sup> Meditation consists of various techniques that regulate the mind to produce a desired mental state. Examples of meditative techniques are mantra-based meditation, relaxation response, mindfulness meditation, Transcendental Meditation, Vipassana meditation, and Zen meditation.

For therapies that include movement, such as yoga and tai chi, mind-body therapies can be a form of exercise for patients with diabetes. According to ADA, patients with diabetes should be advised to perform at least 150 minutes/week of moderate-

intensity aerobic physical activity.<sup>66</sup> The exercise intensity of yoga and tai chi has been categorized as low- to moderate-intensity.<sup>67-70</sup> However, in controlled clinical trials, neither yoga<sup>71,72</sup> nor tai chi<sup>73-77</sup> has consistently demonstrated significant long-term improvements in glycemic control or A1C.

Chronic diseases such as diabetes are associated with diminished quality of life and psychological depression and anxiety. Mind-body therapies have behavioral and psychological effects that may help patients cope with disease and improve mood and quality of life.<sup>78</sup> Among patients with diabetes, clinical trials have shown improvement in measures of quality of life and stress with yoga and tai chi practice.<sup>73,79-81</sup> Very few studies of meditation have been conducted in patients with type 2 diabetes.<sup>78,82</sup>

The risks of practicing mind-body medicine are minimal, and movement-based practices such as tai chi and yoga probably have equivalent risk to conventional exercise. Overall, the quality of published research for mind-body interventions for patients with diabetes is poor, and more rigorous study is necessary.

**Advising Patients With Diabetes About CAM Therapies**

Health care providers treating patients with diabetes should ask patients about their use of CAM therapies. Given the low disclosure of CAM use by patients to physicians, clinicians need to actively inquire about such therapies.

When collecting information about medications in a patient history, clinicians should also ask about the use of herbs and dietary supplements. Mind-body practices can be reviewed in the context of social history when evaluating physical

activity and assessing strategies to deal with stress.

Because patients often self-select CAM modalities, providers should ask patients why they chose a particular therapy. This will help providers understand patients' knowledge and beliefs about the therapy and foster communication between providers and patients.

After identifying CAM use, physicians can access resources to evaluate further clinical efficacy and safety. Table 3 outlines both public and proprietary resources for clinicians and patients. Checking resources for potential interactions with chronic medications is important to avoid adverse effects. Dietary supplements reviewed in Table 1 may augment the effect of conventional glucose-lowering medications, producing hypoglycemia.

In advising patients on CAM use for diabetes, physicians need to weigh the evidence of efficacy and safety (Table 4).<sup>83</sup> For CAM modalities that are clearly ineffective and may be unsafe, discouraging patients is most appropriate. In contrast, when there is convincing information for efficacy and safety, providers may recommend use. Many CAM therapies for diabetes have inconclusive data on efficacy but are probably safe. In such cases, patient counseling and monitored use is reasonable.

Patients taking herbs or supplements concurrent with medications may require more frequent evaluation to identify potential interactions. Providers can also highlight the cost of CAM therapies to patients, especially when efficacy is doubtful. Because of limited

**Table 3. Resources for Information on CAM**

| Resource   | Content  |
|--|--|
| <b>Public</b>  |  |
| National Center for Complementary and Alternative Medicine (nccam.nih.gov)                     | <ul style="list-style-type: none"> <li>• Definitions of CAM modalities, general recommendations, and current clinical trials</li> </ul>                    |
| Office of Dietary Supplements (www.ods.od.nih.gov/index.aspx)                                  | <ul style="list-style-type: none"> <li>• Description of dietary supplements, including scientific evidence on botanicals</li> </ul>                        |
| Medline Plus Drugs and Supplement Directory (www.nlm.nih.gov/medlineplus/druginformation.html) | <ul style="list-style-type: none"> <li>• Description of dietary supplements, including monographs</li> </ul>   |
| <b>Proprietary</b>   |  |
| Natural Medicines Comprehensive Database (www.naturaldatabase.com)                             | <ul style="list-style-type: none"> <li>• Description of dietary supplements, including monographs, scientific evidence, and interaction checker</li> </ul> |
| Natural Standard (www.naturalstandard.com)   | <ul style="list-style-type: none"> <li>• Description of dietary supplements, including monographs, scientific evidence, and interaction checker</li> </ul> |
| Consumerlab.com (www.consumerlab.com)  | <ul style="list-style-type: none"> <li>• Independently evaluates manufactured botanicals for ingredients and contaminants</li> </ul>                       |

**Table 4. Advising Patients on CAM Use**

| Evidence of Efficacy | Evidence of Safety | Advice              |
|----------------------|--------------------|---------------------|
| High                 | High               | Recommend           |
| Inconclusive         | High               | Counsel and monitor |
| High                 | Inconclusive       | Counsel and monitor |
| Inconclusive or low  | Low/unsafe         | Discourage          |

*Adapted from Ref. 83.*

data, women who are pregnant or lactating and children should be cautioned about the unknown potential adverse effects of dietary supplements.

When patients choose to take a botanical or dietary supplement, providers may be asked to recommend specific products. Given the manufacturing and regulatory framework, there is high variability in the content and quality of products sold. Consumers may use a third-party resource such as Consumer Labs (www.ConsumerLabs.com) to identify dietary supplements with higher integrity. Another option is to use formulations already shown to be safe and effective in clinical trials.

**Conclusion**

A high prevalence of patients with diabetes use CAM therapies, and health care providers need to be prepared to counsel such patients. Frequently, CAM modalities used for diabetes are biologically based therapies and mind-body medicine. Biologically based practices, including herbs and dietary supplements, can affect glucose metabolism, but evidence for their clinical use in patients with diabetes is scarce. Mind-body practices may offer a healthy lifestyle change for patients with diabetes, but long-term improvements in glycemic control have not been shown in clinical trials.

Regulation of botanical products in the United States allows for mar-

keting without established efficacy or safety. Physicians need to specifically ask about supplement use and monitor patients for potential adverse effects, especially hypoglycemia in patients with diabetes.

When counseling patients on CAM use, physicians should respect patients' choices regarding self-management, while providing evidence-based information about efficacy and safety or the lack thereof. Despite unclear data, a large number of patients will continue using CAM in the future. As research grows in this field, physicians have an opportunity to help patients make decisions about the most safe and effective CAM therapies to consider.

**REFERENCES**

<sup>1</sup>National Center for Complementary and Alternative Medicine, National Institutes of Health: What is CAM? [article online] Available from <http://nccam.nih.gov/health/whatiscam/overview.htm>. Accessed 24 May 2010

<sup>2</sup>Snyderman R, Weil AT: Integrative medicine: bringing medicine back to its roots. *Arch Intern Med* 162:395–397, 2002

<sup>3</sup>Barnes PM, Bloom B, Nahin RL: Complementary and alternative medicine use among adults and children: United States, 2007. *Natl Health Stat Rep* 12:1–23, 2009

<sup>4</sup>Bell RA, Suerken CK, Grzywacz JG, Lang W, Quandt SA, Arcury TA: Complementary and alternative medicine use among adults with diabetes in the United States. *Altern Ther Health Med* 12:16–22, 2006

<sup>5</sup>Nahin RL, Barnes PM, Stussman BJ, Bloom B: Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. *Natl Health Stat Rep* 18:1–14, 2009

<sup>6</sup>Kennedy DA, Seely D: Clinically based evidence of drug-herb interactions: a system-

atic review. *Expert Opin Drug Saf* 9:79–124, 2010

<sup>7</sup>Gardiner P, Graham RE, Legedza AT, Eisenberg DM, Phillips RS: Factors associated with dietary supplement use among prescription medication users. *Arch Intern Med* 166:1968–1974, 2006

<sup>8</sup>Eisenberg DM, Kessler RC, Van Rompuy MI, Kaptchuk TJ, Wilkey SA, Appel S, Davis RB: Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. *Ann Intern Med* 135:344–351, 2001

<sup>9</sup>Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML: Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. *Diabetes Care* 31 (Suppl. 1):S61–S78, 2008

<sup>10</sup>Reinhart KM, Talati R, White CM, Coleman CI: The impact of garlic on lipid parameters: a systematic review and meta-analysis. *Nutr Res Rev* 22:39–48, 2009

<sup>11</sup>Stevinson C, Pittler MH, Ernst E: Garlic for treating hypercholesterolemia: a meta-analysis of randomized clinical trials. *Ann Intern Med* 133:420–429, 2000

<sup>12</sup>Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T: Effect of garlic on blood pressure: a systematic review and meta-analysis. *BMC Cardiovasc Disord* 8:13, 2008

<sup>13</sup>Ajabnoor MA: Effect of aloes on blood glucose levels in normal and alloxan diabetic mice. *J Ethnopharmacol* 28:215–220, 1990

<sup>14</sup>Ghannam N, Kingston M, Al-Meshaal IA, Tariq M, Parman NS, Woodhouse N: The antidiabetic activity of aloes: preliminary clinical and experimental observations. *Horm Res* 24:288–294, 1986

<sup>15</sup>Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V, Chochechairoenporn O: Antidiabetic activity of aloe vera L. juice. II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. *Phytomed* 3:245–248, 1996

<sup>16</sup>Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, Chochechairoenporn O: Antidiabetic activity of aloe vera L. juice. I. Clinical trial in new cases of diabetes mellitus. *Phytomed* 3:241–243, 1996

<sup>17</sup>Siegers CP, von Hertzberg-Lottin E, Otte M, Schneider B: Anthranoid laxative abuse: a risk for colorectal cancer? *Gut* 34:1099–1101, 1993

<sup>18</sup>Kamble SM, Kamlakar PL, Vaidya S, Bambole VD: Influence of *Coccinia indica* on certain enzymes in glycolytic and lipolytic pathway in human diabetes. *Indian J Med Sci* 52:143–146, 1998

<sup>19</sup>Azad Khan AK, Akhtar S, Mahtab H: *Coccinia indica* in the treatment of patients with diabetes mellitus. *Bangladesh Med Res Counc Bull* 5:60–66, 1979

<sup>20</sup>Kuriyan R, Rajendran R, Bantwal G, Kurpad AV: Effect of supplementation of *Coccinia cordifolia* extract on newly detected

- diabetic patients. *Diabetes Care* 31:216–220, 2008
- <sup>21</sup>Preuss HG, Jarrell ST, Scheckenbach R, Lieberman S, Anderson RA: Comparative effects of chromium, vanadium and gymnema sylvestre on sugar-induced blood pressure elevations in SHR. *J Am Coll Nutr* 17:116–123, 1998
- <sup>22</sup>Shanmugasundaram ER, Gopinath KL, Radha Shanmugasundaram K, Rajendran VM: Possible regeneration of the islets of Langerhans in streptozotocin-diabetic rats given *Gymnema sylvestre* leaf extracts. *J Ethnopharmacol* 30:265–279, 1990
- <sup>23</sup>Shanmugasundaram ER, Rajeswari G, Baskaran K, Rajesh Kumar BR, Radha Shanmugasundaram K, Kizar Ahmath B: Use of *Gymnema sylvestre* leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. *J Ethnopharmacol* 30:281–294, 1990
- <sup>24</sup>Baskaran K, Kizar Ahmath B, Radha Shanmugasundaram K, Shanmugasundaram ER: Antidiabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. *J Ethnopharmacol* 30:295–300, 1990
- <sup>25</sup>Krawinkel MB, Keding GB: Bitter gourd (*Momordica Charantia*): a dietary approach to hyperglycemia. *Nutr Rev* 64:331–337, 2006
- <sup>26</sup>Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S: Anti-diabetic and hypoglycaemic effects of *Momordica charantia* (bitter melon): a mini review. *Br J Nutr* 102:1703–1708, 2009
- <sup>27</sup>Shibib BA, Khan LA, Rahman R: Hypoglycaemic activity of *Coccinia indica* and *Momordica charantia* in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. *Biochem J* 292:267–270, 1993
- <sup>28</sup>Ng TB, Wong CM, Li WW, Yeung HW: Insulin-like molecules in *Momordica charantia* seeds. *J Ethnopharmacol* 15:107–117, 1986
- <sup>29</sup>Ng TB, Wong CM, Li WW, Yeung HW: Isolation and characterization of a galactose binding lectin with insulin-mimetic activities: from the seeds of the bitter gourd *Momordica charantia* (Family Cucurbitaceae). *Int J Pept Protein Res* 28:163–172, 1986
- <sup>30</sup>Ooi CP, Yassin Z, Hamid TA: *Momordica charantia* for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2:CD007845, 2010
- <sup>31</sup>Coronado GD, Thompson B, Tejeda S, Godina R: Attitudes and beliefs among Mexican Americans about type 2 diabetes. *J Health Care Poor Underserved* 15:576–588, 2004
- <sup>32</sup>Fрати AC, Gordillo BE, Altamirano P, Ariza CR, Cortes-Franco R, Chavez-Negrete A, Islas-Andrade S: Influence of nopal intake upon fasting glycemia in type II diabetics and healthy subjects. *Arch Invest Med (Mex)* 22:51–56, 1991
- <sup>33</sup>Fрати-Munari AC, Gordillo BE, Altamirano P, Ariza CR: Hypoglycemic effect of *Opuntia streptacantha* Lemaire in NIDDM. *Diabetes Care* 11:63–66, 1988
- <sup>34</sup>Shapiro K, Gong WC: Natural products used for diabetes. *J Am Pharm Assoc (Wash)* 42:217–226, 2002
- <sup>35</sup>Buettner C, Yeh GY, Phillips RS, Mittleman MA, Kaptchuk TJ: Systematic review of the effects of ginseng on cardiovascular risk factors. *Ann Pharmacother* 40:83–95, 2006
- <sup>36</sup>Dascalu A, Sievenpiper JL, Jenkins AL, Stavro MP, Leiter LA, Arnason JT, Vuksan V: Five batches representative of Ontario-grown American ginseng root produce comparable reductions of postprandial glycemia in healthy individuals. *Can J Physiol Pharmacol* 85:856–864, 2007
- <sup>37</sup>Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V: Variable effects of American ginseng: a batch of American ginseng (*Panax quinquefolius* L.) with a depressed ginsenoside profile does not affect postprandial glycemia. *Eur J Clin Nutr* 57:243–248, 2003
- <sup>38</sup>Srinivasan K: Plant foods in the management of diabetes mellitus: spices as beneficial antidiabetic food adjuncts. *Int J Food Sci Nutr* 56:399–414, 2005
- <sup>39</sup>Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS: Systematic review of herbs and dietary supplements for glycemic control in diabetes. *Diabetes Care* 26:1277–1294, 2003
- <sup>40</sup>Singh U, Jialal I: Alpha-lipoic acid supplementation and diabetes. *Nutr Rev* 66:646–657, 2008
- <sup>41</sup>Jacob S, Henriksen EJ, Schiemann AL, Simon I, Clancy DE, Tritschler HJ, Jung WI, Augustin HJ, Dietze GJ: Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. *Arzneimittelforschung* 45:872–874, 1995
- <sup>42</sup>Jacob S, Henriksen EJ, Tritschler HJ, Augustin HJ, Dietze GJ: Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. *Exp Clin Endocrinol Diabetes* 104:284–288, 1996
- <sup>43</sup>Kamenova P: Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. *Hormones (Athens)* 5:251–258, 2006
- <sup>44</sup>Evans JL, Heymann CJ, Goldfine ID, Gavin LA: Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. *Endocr Pract* 8:29–35, 2002
- <sup>45</sup>Anderson RA, Bryden NA, Polansky MM: Dietary chromium intake: freely chosen diets, institutional diet, and individual foods. *Biol Trace Elem Res* 32:117–121, 1992
- <sup>46</sup>Freund H, Atamian S, Fischer JE: Chromium deficiency during total parenteral nutrition. *JAMA* 241:496–498, 1979
- <sup>47</sup>Schroeder HA: Chromium deficiency in rats: a syndrome simulating diabetes mellitus with retarded growth. *J Nutr* 88:439–445, 1966
- <sup>48</sup>Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG: Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. *Diabetes Care* 30:2154–2163, 2007
- <sup>49</sup>Cefalu WT, Rood J, Pinsonat P, Qin J, Sereda O, Levitan L, Anderson RA, Zhang XH, Martin JM, Martin CK, Wang ZQ, Newcomer B: Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. *Metabolism* 59:755–762, 2010
- <sup>50</sup>Wang ZQ, Cefalu WT: Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. *Curr Diab Rep* 10:145–151, 2010
- <sup>51</sup>Wang ZQ, Qin J, Martin J, Zhang XH, Sereda O, Anderson RA, Pinsonat P, Cefalu WT: Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. *Metabolism* 56:1652–1655, 2007
- <sup>52</sup>Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD: Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. *Eur J Clin Nutr* 56:1137–1142, 2002
- <sup>53</sup>Eriksson JG, Forsen TJ, Mortensen SA, Rohde M: The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. *BioFactors* 9:315–318, 1999
- <sup>54</sup>Tosiello L: Hypomagnesemia and diabetes mellitus: a review of clinical implications. *Arch Intern Med* 156:1143–1148, 1996
- <sup>55</sup>Song Y, He K, Levitan EB, Manson JE, Liu S: Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. *Diabet Med* 23:1050–1056, 2006
- <sup>56</sup>Larsson SC, Wolk A: Magnesium intake and risk of type 2 diabetes: a meta-analysis. *J Intern Med* 262:208–214, 2007
- <sup>57</sup>Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, Durrington PN, Ness AR, Capps NE, Davey Smith G, Riemersma RA, Ebrahim SB: Omega 3 fatty acids for prevention and treatment of cardiovascular disease. *Cochrane Database Syst Rev* CD003177, 2004
- <sup>58</sup>Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J: n-3 fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. *Am J Clin Nutr* 84:5–17, 2006
- <sup>59</sup>Hartweg J, Perera R, Montori V, Dinneen S, Neil HA, Farmer A: Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. *Cochrane Database Syst Rev* CD003205, 2008
- <sup>60</sup>Kaushik M, Mozaffarian D, Spiegelman D, Manson JE, Willett WC, Hu FB: Long-chain omega-3 fatty acids, fish intake, and



the risk of type 2 diabetes mellitus. *Am J Clin Nutr* 90:613–620, 2009

<sup>61</sup>Vanadium (vanadyl sulfate) [monograph]. *Altern Med Rev* 14:177–180, 2009

<sup>62</sup>Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. *J Clin Invest* 95:2501–2509, 1995

<sup>63</sup>Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky GR, Kahn CR: Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. *Metabolism* 49:400–410, 2000

<sup>64</sup>Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H: Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. *Diabetes* 45:659–666, 1996

<sup>65</sup>Wayne PM, Kaptchuk TJ: Challenges inherent to t'ai chi research: part I: t'ai chi as a complex multicomponent intervention. *J Altern Complement Med* 14:191–197, 2008

<sup>66</sup>American Diabetes Association: Executive summary: standards of medical care in diabetes—2010. *Diabetes Care* 33 (Suppl. 1):S4–S10, 2010

<sup>67</sup>Clay CC, Lloyd LK, Walker JL, Sharp KR, Pankey RB: The metabolic cost of hatha yoga. *J Strength Cond Res* 19:604–610, 2005

<sup>68</sup>Hagins M, Moore W, Rundle A: Does practicing hatha yoga satisfy recommendations for intensity of physical activity which improves and maintains health and cardiovascular fitness? *BMC Complement Altern Med* 7:40, 2007

<sup>69</sup>Chao YF, Chen SY, Lan C, Lai JS: The cardiorespiratory response and energy expenditure of Tai-Chi-Qui-Gong. *Am J Chin Med* 30:451–461, 2002

<sup>70</sup>Hui SS, Woo J, Kwok T: Evaluation of energy expenditure and cardiovascular health

effects from Tai Chi and walking exercise. *Hong Kong Med J* 15 (Suppl. 2):4–7, 2009

<sup>71</sup>Aljasir B, Bryson M, Al-Shehri B: Yoga practice for the management of type II diabetes mellitus in adults: a systematic review. *Evid Based Complement Alternat Med* 7:399–408, 2010

<sup>72</sup>Innes KE, Vincent HK: The influence of yoga-based programs on risk profiles in adults with type 2 diabetes mellitus: a systematic review. *Evid Based Complement Alternat Med* 4:469–486, 2007

<sup>73</sup>Lam P, Dennis SM, Diamond TH, Zwan N: Improving glycaemic and BP control in type 2 diabetes: the effectiveness of tai chi. *Aust Fam Phys* 37:884–887, 2008

<sup>74</sup>Lee MS, Pittler MH, Kim MS, Ernst E: Tai chi for type 2 diabetes: a systematic review. *Diabet Med* 25:240–241, 2008

<sup>75</sup>Tsang T, Orr R, Lam P, Comino E, Singh MF: Effects of tai chi on glucose homeostasis and insulin sensitivity in older adults with type 2 diabetes: a randomised double-blind sham-exercise-controlled trial. *Age Ageing* 37:64–71, 2008

<sup>76</sup>Tsang T, Orr R, Lam P, Comino EJ, Singh MF: Health benefits of tai chi for older patients with type 2 diabetes: the “Move It for Diabetes” study: a randomized controlled trial. *Clin Interv Aging* 2:429–439, 2007

<sup>77</sup>Zhang Y, Fu FH: Effects of 14-week tai ji quan exercise on metabolic control in women with type 2 diabetes. *Am J Chin Med* 36:647–654, 2008

<sup>78</sup>Ospina MB, Bond K, Karkhaneh M, Tjosvold L, Vandermeer B, Liang Y, Bialy L, Hooton N, Buscemi N, Dryden DM, Klassen TP: Meditation practices for health: state of research. *Evid Rep Technol Assess* 155:1–263, 2007

<sup>79</sup>Kosuri M, Sridhar GR: Yoga practice in diabetes improves physical and psychological outcomes. *Metab Syndr Relat Disord* 7:515–517, 2009

<sup>80</sup>Song R, Ahn S, Roberts BL, Lee EO, Ahn YH: Adhering to a t'ai chi program to

improve glucose control and quality of life for individuals with type 2 diabetes. *J Altern Complement Med* 15:627–632, 2009

<sup>81</sup>Yang K, Bernardo LM, Sereika SM, Conroy MB, Balk J, Burke LE: Utilization of 3-month yoga program for adults at high risk for type 2 diabetes: a pilot study. *Evid Based Complement Alternat Med* Electronically published ahead of print. DOI:10.1093/ecam/nep117

<sup>82</sup>Rosenzweig S, Reibel DK, Greenson JM, Edman JS, Jasser SA, McMearty KD, Goldstein BJ: Mindfulness-based stress reduction is associated with improved glycaemic control in type 2 diabetes mellitus: a pilot study. *Altern Ther Health Med* 13:36–38, 2007

<sup>83</sup>Cohen MH, Eisenberg DM: Potential physician malpractice liability associated with complementary and integrative medical therapies. *Ann Intern Med* 136:596–603, 2002

---

*Gurjeet S. Birdee, MD, MPH, is an assistant professor in the Division of Internal Medicine and Pediatrics and Vanderbilt Center for Integrative Health at Vanderbilt University Medical Center in Nashville, Tenn. Gloria Yeh, MD, MPH, is an associate professor in the Division for Research and Education in Complementary and Integrative Medical Therapies at the Osher Research Center and in the Division of General Medicine and Primary Care, Department of Medicine, at Beth Israel Deaconess Medical Center of Harvard Medical School in Boston, Mass.*